The effect of rebamipide on non-steroidal antiinflammatory drug-induced gastro-enteropathy: a multi-center, randomized pilot study
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly-used medications, and ailments such as arthritis or heart disease, require long-term use of these drugs, which can induce gastroenteropathy with bleeding and ulcers. This study investigated the associations between efficacy, safety, and gastrointestinal symptoms linked to rebamipide and proton pump inhibitor administration in patients requiring long-term NSAID use. Methods: This study was a multi-center, randomized, open-labeled, pilot design. Results: Thirty-three patients were included. Of these, 15 were included in the study group and 18 were in the control group. NSAID-induced gastric ulcers, which were the primary outcome of this study, did not occur in either the study or control group. Changes in the number of small bowel erosions and ulcers were –0.6 ± 3.06 in the study group and 1.33 ± 4.71 in the control group. The number of subjects with mucosal breaks (defined as multiple erosions and/or ulcers) was three (20%) in the study group and six (40%) in the control group (p = 0.427). No serious adverse events occurred in either group. However, dyspepsia and skin rashes occurred in six patients (31.58%) in the study group and 13 (65%) in the control group (p = 0.036). Conclusions: Although statistically significant differences were not generated, possibly as a result of the small sample size, mucosal breaks observed via capsule endoscopy revealed that rebamipide was likely to be more effective than lansoprazole in preventing small intestine damage caused by NSAIDs. Furthermore, fewer side-effects emerged with rebamipide.
Abstract
Background/Aims: Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly-used medications, and ailments such as arthritis or heart disease, require long-term use of these drugs, which can induce gastroenteropathy with bleeding and ulcers. This study investigated the associations between efficacy, safety, and gastrointestinal symptoms linked to rebamipide and proton pump inhibitor administration in patients requiring long-term NSAID use. Methods: This study was a multi-center, randomized, open-labeled, pilot design. Results: Thirty-three patients were included. Of these, 15 were included in the study group and 18 were in the control group. NSAID-induced gastric ulcers, which were the primary outcome of this study, did not occur in either the study or control group. Changes in the number of small bowel erosions and ulcers were –0.6 ± 3.06 in the study group and 1.33 ± 4.71 in the control group. The number of subjects with mucosal breaks (defined as multiple erosions and/or ulcers) was three (20%) in the study group and six (40%) in the control group (p = 0.427). No serious adverse events occurred in either group. However, dyspepsia and skin rashes occurred in six patients (31.58%) in the study group and 13 (65%) in the control group (p = 0.036). Conclusions: Although statistically significant differences were not generated, possibly as a result of the small sample size, mucosal breaks observed via capsule endoscopy revealed that rebamipide was likely to be more effective than lansoprazole in preventing small intestine damage caused by NSAIDs. Furthermore, fewer side-effects emerged with rebamipide.
참고문헌 (52)
- Laine L, "Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient", Gastroenterology, 120, pp.594~606 (2001)
- Maiden L, "Capsule endoscopic diagnosis of nonsteroidal antiinflammatory drug-induced enteropathy", J Gastroenterol, 44(Suppl 19), pp.64~71 (2009)
- Hawkey CJ, "Non-steroidal anti-inflammatory drugs and peptic ulcers", BMJ, 300, pp.278~284 (1990)
- Fujimori S, "Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury : a double-blind, randomized, controlled trial evaluated by capsule endoscopy", J Gastroenterol, 46, pp.57~64 (2011)
- Regula J, "Prevention of NSAID-associated gastrointestinal lesions : a comparison study pantoprazole versus omeprazole", Am J Gastroenterol, 101, pp.1747~1755 (2006)
- Peura DA, "Balancing the gastrointestinal benefits and risks of nonselective NSAIDs", Arthritis Res Ther, 7(Suppl 4), pp.S7~S13 (2005)
- Singh G, "Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage", Int J Clin Pract, 59, pp.1210~1217 (2005)
- Boparai V, "Guide to the use of proton pump inhibitors in adult patients", Drugs, 68, pp.925~947 (2008)
- Cheer SM, "Pantoprazole : an update of its pharmacological properties and therapeutic use in the management of acid-related disorders", Drugs, 63, pp.101~133 (2003)
- Higuchi K, "Prevention of NSAID-induced small intestinal mucosal injury : prophylactic potential of lansoprazole", J Clin Biochem Nutr, 45, pp.125~130 (2009)
- Yoda Y, "Prevention by lansoprazole, a proton pump inhibitor, of indomethacin-induced small intestinal ulceration in rats through induction of heme oxygenase-1", J Physiol Pharmacol, 61, pp.287~294 (2010)
- Zhang S, "Proton pump inhibitors are not the key for therapying non-steroidal anti-inflammatory drugs-induced small intestinal injury", Rheumatol Int, 33, pp.2513~2521 (2013)
- Lim YJ, "In vitro and in vivo protection against indomethacin-induced small intestinal injury by proton pump inhibitors, acid pump antagonists, or indomethacin-phosphatidylcholine", Digestion, 86, pp.171~177 (2012)
- Wallace JL, "Prostaglandins, NSAIDs, and gastric mucosal protection : why doesn’t the stomach digest itself?", Physiol Rev, 88, pp.1547~1565 (2008)
- Park SC, "Prevention and management of non-steroidal anti-inflammatory drugs-induced small intestinal injury", World J Gastroenterol, 17, pp.4647~4653 (2011)
- Yamasaki K, "Effect of OPC-12759, a novel antiulcer agent, on chronic and acute experimental gastric ulcer, and gastric secretion in rats", Jpn J Pharmacol, 49, pp.441~448 (1989)
- Arakawa T, "Rebamipide, novel prostaglandin-inducer accelerates healing and reduces relapse of acetic acid-induced rat gastric ulcer. Comparison with cimetidine", Dig Dis Sci, 40, pp.2469~2472 (1995)
- Takagi T, "Rebamipide promotes healing of colonic ulceration through enhanced epithelial restitution", World J Gastroenterol, 17, pp.3802~3809 (2011)
- Graham DY, "Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs : results of a double-blind, randomized, multicenter, active-and placebo-controlled study of misoprostol vs lansoprazole", Arch Intern Med, 162, pp.169~175 (2002)
- Park SH, "Comparison of prevention of NSAID-induced gastrointestinal complications by rebamipide and misoprostol : a randomized, multicenter, controlled trial-STORM Study", J Clin Biochem Nutr, 40, pp.148~155 (2007)
- Musumba C, "Review article : cellular and molecular mechanisms of NSAID-induced peptic ulcers", Aliment Pharmacol Ther, 30, pp.517~531 (2009)
- Sinha M, "Current perspectives in NSAID-induced gastropathy", Mediators Inflamm, 2013, pp.258209~ (2013)
- Takeuchi K, "Pathogenesis of NSAID-induced gastric damage : importance of cyclooxygenase inhibition and gastric hypermotility", World J Gastroenterol, 18, pp.2147~2160 (2012)
- Mitchell JA, "Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase", Proc Natl Acad Sci U S A, 90, pp.11693~11697 (1993)
- Laine L, "Nonsteroidal anti-inflammatory drug gastropathy", Gastrointest Endosc Clin N Am, 6, pp.489~504 (1996)
- Miller TA, "Protective effects of prostaglandins against gastric mucosal damage : current knowledge and proposed mechanisms", Am J Physiol, 245(5 Pt 1), pp.G601~G623 (1983)
- 이준행, "비스테로이드소염제 관련 소화성궤양의 예방과 치료 가이드라인", 대한소화기학회지, 54(5), pp.309~317 (2009), 대한소화기학회
- Lanza FL, "Guidelines for prevention of NSAID-related ulcer complications", Am J Gastroenterol, 104, pp.728~738 (2009)
- Rostom A, "Prevention of NSAID-induced gastroduodenal ulcers", Cochrane Database Syst Rev, 4, pp.CD002296~ (2002)
- Lanas A, "Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice", Am J Gastroenterol, 104, pp.1633~1641 (2009)
- Cavallaro LG, "Time trends and outcome of gastrointestinal bleeding in the Veneto region : a retrospective population based study from 2001 to 2010", Dig Liver Dis, 46, pp.313~317 (2014)
- Silverstein FE, "Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis : the CLASS study : a randomized controlled trial : Celecoxib Long-term Arthritis Safety Study", JAMA, 284, pp.1247~1255 (2000)
- Wallace JL, "Pathogenesis of NSAID-induced gastroduodenal mucosal injury", Best Pract Res Clin Gastroenterol, 15, pp.691~703 (2001)
- Kent TH, "Small intestinal ulcers and intestinal flora in rats given indomethacin", Am J Pathol, 54, pp.237~249 (1969)
- Sakurai K, "Mechanism of hydroxyl radical scavenging by rebamipide : identification of mono-hydroxylated rebamipide as a major reaction product", Free Radic Res, 38, pp.487~494 (2004)
- Chitapanarux T, "An open-labeled study of rebamipide treatment in chronic gastritis patients with dyspeptic symptoms refractory to proton pump inhibitors", Dig Dis Sci, 53, pp.2896~2903 (2008)
- Lanas A, "Nonsteroidal anti-inflammatory drugs and lower gastrointestinal complications", Gastroenterol Clin North Am, 38, pp.333~352 (2009)
- Dial EJ, "In vitro evidence that phosphatidylcholine protects against indomethacin", bile acid-induced injury to cells, 2015, pp.308, G217~G222
- Handa O, "The impact of non-steroidal anti-inflammatory drugs on the small intestinal epithelium", J Clin Biochem Nutr, 54, pp.2~6 (2014)
- Scarpignato C, "Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract : clinical picture, pathogenesis, and prevention", Gastroenterol Clin North Am, 39, pp.433~464 (2010)
- Washio E, "Proton pump inhibitors increase incidence of nonsteroidal anti-inflammatory drug-induced small bowel injury : a randomized, placebo-controlled trial", Clin Gastroenterol Hepatol, 14, pp.809~815 (2016)
- Wallace JL, "Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis", Gastroenterology, 141, pp.1314~1322 (2011)
- Wallace JL, "NSAID gastropathy and enteropathy : distinct pathogenesis likely necessitates distinct prevention strategies", Br J Pharmacol, 165, pp.67~74 (2012)
- Goldstein JL, "Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo", Clin Gastroenterol Hepatol, 3, pp.133~141 (2005)
- Maiden L, "A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy", Gastroenterology, 128, pp.1172~1178 (2005)
- Fujimori S, "Distribution of small intestinal mucosal injuries as a result of NSAID administration", Eur J Clin Invest, 40, pp.504~510 (2010)
- Mizoguchi H, "Protective effect of rebamipide on indomethacin-induced intestinal damage in rats", J Gastroenterol Hepatol, 16, pp.1112~1119 (2001)
- Mizukami K, "Aspirin-induced small bowel injuries and the preventive effect of rebamipide", World J Gastroenterol, 17, pp.5117~5122 (2011)
- Kurokawa S, "A randomized, double-blinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and", or non-steroidal anti-inflammatory drug induced small bowel injury, 2014, pp.49, 239~244
- Niwa Y, "Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects : a prospective, randomized, double-blinded, placebo-controlled, cross-over study", J Gastroenterol, 43, pp.270~276 (2008)
- Diao L, "Rebamipide suppresses diclofenac-induced intestinal permeability via mitochondrial protection in mice", World J Gastroenterol, 18, pp.1059~1066 (2012)
- Tanigawa T, "Rebamipide inhibits indomethacin-induced small intestinal injury : possible involvement of intestinal microbiota modulation by upregulation of α-defensin 5", Eur J Pharmacol, 704, pp.64~69 (2013)